Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Method and therapeutic system for administering scopolamine transdermally|
|Abstract:||Method and therapeutic system in the form of a bandage that administer scopolamine base transdermally in an initial pulse of 10 to 200 .mu.g/cm.sup.2 of skin that quickly brings the concentration of scopolamine in the plasma to a level at which emesis and nausea are inhibited without intolerable side effects, followed by a substantially constant dosage in the range of 0.3 to 15 .mu.g/hr that holds said level. The bandage is a four-layer laminate of, from the top: a protective backing; a gelled, mineral oil-polyisobutene-scopolamine reservoir lamina that is the source of the constant dosage; a microporous membrane that controls the constant dosage rate; and a gelled, mineral oil-polyisobutene-scopolamine adhesive layer that is the source of the pulse dose and the means by which the bandage is attached to the skin.|
|Inventor(s):||Urquhart; John (Palo Alto, CA), Chandrasekaran; Kumar (Palo Alto, CA), Shaw; Jane (Atherton, CA)|
|Assignee:||Alza Corporation (Palo Alto, CA)|
1. Method for inhibiting emesis and nausea for a prolonged time period comprising administering scopolamine base to unbroken skin in an initial pulse of about 10 to about 200
.mu.g/cm.sup.2 of skin and thereafter at a substantially constant rate in the range of about 0.3 to about 15 .mu.g/hr for as long as therapy is required.
2. The method of claim 1 wherein the emesis and nausea arre induced by a vestibular disturbance and the administration begins at least about 3 hr before the disturbance requires therapy.
3. The method of claim 1 wherein the total quantity of scopolamine base administered is in the range of 0.1 to 2.5 mg.
4. The method of claim 1 wherein the skin is located at the mastoidal area.
5. The method of claim 1 wherein the skin is at a body site other than a mastoidal area and the skin is treated with an effective amount of a skin permeation enhancing agent.
6. The method of claim 5 wherein the skin permeation enhancing agent is selected from the group consisting of dimethyl lauramide, dimethyl sulfoxide, and dodecyl pyrrolidone.
7. The method of claim 1 wherein the initial pulse is about 50 to about 150 .mu.g/cm.sup.2 of skin and the substantially constant rate is about 5 to 15 .mu.g/hr for adults and 3 to 10 .mu.g/hr for children.
8. A method of claim 7 wherein the skin is located at a mastoidal area.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.